Document is current
Any future updates will be listed below
-
Authors
Verdonschot, Job A. J. https://orcid.org/0000-0001-5549-1298
Ferreira, João Pedro
Pellicori, Pierpaolo
Brunner-La Rocca, Hans-Peter
Clark, Andrew L.
Cosmi, Franco
Cuthbert, Joe
Girerd, Nicolas
Mariottoni, Beatrice
Petutschnigg, Johannes
Rossignol, Patrick
Cleland, John G. F.
Zannad, Faiez
Heymans, Stephane R. B.
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02556450 at ClinicalTrials.govDocuments that mention this clinical trial
Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
https://doi.org/10.1186/s12933-021-01357-9
Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure
https://doi.org/10.1136/heartjnl-2018-313182
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
https://doi.org/10.1136/heartjnl-2023-323796
-
Funding
Funding for this research was provided by:
FP7 International Cooperation (305507)
- License Information
-
More Information
Article History
Received: 3 June 2021
Accepted: 29 July 2021
First Online: 9 August 2021
Declarations
:
: The study was approved by all relevant ethics committees and regulatory bodies. All participants provided written informed consent prior to study-specific procedures.
: There is no data of individual persons included in the manuscript.
: The authors have no relevant conflicts of interest to disclose with regards to the content of this manuscript.
